期刊文献+

肺癌组织p53、HER-2蛋白的表达及意义 被引量:5

SIGNIFICANCE OF P53、HER-2 PROTEIN EXPRESSION IN LUNG CANCER TISSUE
下载PDF
导出
摘要 目的 :探讨 p5 3、HER - 2蛋白在肺癌的表达及意义。方法 :应用免疫组织化学S -P法检测肺癌组织中p5 3、HER - 2蛋白表达。结果 :p5 3、HER - 2蛋白在 5 1例肺癌组织中的阳性表达率分别为 5 8.82 % ,5 6 .86 %。其中p5 3蛋白在鳞癌、腺鳞癌和腺癌的表达无显著性差异 (P >0 .0 5 ) ,但有淋巴结转移者(77.2 7% )显著高于无淋巴结转移者 (4 4.82 % ,P <0 .0 5 ) ;HER - 2蛋白阳性表达在腺癌、腺鳞癌均为75 .0 0 % ,显著高于鳞癌 (34 .78% ,P <0 .0 5 ) ,与淋巴结转移也显著相关 (P <0 .0 5 )。结论 :p5 3、HER - 2蛋白阳性的肺癌患者更易发生淋巴结转移 ,HER - Objective:To investigate the significance of P53、HER-2 protein expression in lung cancer tissue.Methods:Immunohistochemistry(S-P)was used to detect P53、HER-2 protein expression in lung cancer tissue.Results:The positive rates of P53、HER-2 protein were 58.82% and 56.86% in lung cancer tissue respectively.There is no marked difference in P53 expression between squamous carcinoma,adeno-squamous carcinoma and adenocarcinoma(P>0.05),but there was a positive correlation with lymph node metastasis (P<0.05).HER-2 expressions in adenocarcinoma(75%) and adeno-squamous carcinoma(75%) were significantly higher than those in squamous carcinoma(34.78%) and also correlated with lymph node metastasis.Conclusions:The lung cancer patients with positive expression of P53 and HER-2 may be more possible to metastasize and there was association between histological type and expression of HER-2.
出处 《中国现代医学杂志》 CAS CSCD 2001年第7期20-21,共2页 China Journal of Modern Medicine
关键词 肺癌 P53蛋白 HER-2蛋白 免疫组织化学 表达 Lung Cancer P53-protein HER-2-protein Immunohistochemistry
  • 相关文献

参考文献9

  • 1Shimosato Y,Sobin LH,Spencer H,et al.The world Health Organization histological typing of lung tumors.Am J Clin Pathol,1982;77:123~129
  • 2Dykins R,Corbett IP,Henry JA,et al.Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein:an immunohistochemical study using monoclonal antibody NCL-CB11.J Pathol,1991;163:105~110
  • 3Tateishi M,Ishida T,Kohdono S,et al.Prognostic influece of the coexpression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma.Surg Oncol,1994;3(2):109~113
  • 4Iggo R,Gatter K,Bartek J,et al.Increased expression of mutant froms of p5[3]oncogene in primary lung cancer.Lancel,1990;335:675~679
  • 5李玲芝,屈全福,顾其华,叶爱慧.非小细胞肺癌与p53基因序列分析[J].中国现代医学杂志,1999,9(12):39-40. 被引量:2
  • 6Oyama T,Osaki T,Nose N,et al.Evaluations of p53 immunoreactivioty,nucleolar organizer regions,and proliferting cell nuclear antigen in non-small cell lung carcinoma.Anticancer Res,2000;20(1B):505~510
  • 7Huncharek Kupelnick B,Geschwind JF,et al.Prognostic significance of p53 mutation in non-small cell lung cancer:a meta-analysis of 829 case from eight published studies.Cancer-Lett,2000;153(1~2):219~226
  • 8Haque AK,Adegboyega P,AI Salameh A,et al.p53 and P-glycoprotein expression do not correlate with survival in non-small cell lung cancer:a long-term study and literture review.Mod Pathol,1999;12(12):1158~1166
  • 9Maruyama R,Sugio K,Fukuyama Y,et al.Evaluation of p53 alterations in occult lymph node metastase.J Surg Oncol,2000;73(3):143~147

二级参考文献4

共引文献1

同被引文献45

  • 1喻伦银,王虹,毕勇毅,刘铭球,邹祖玉,张正彬.p53基因突变与肺癌发生的早期遗传学损害[J].中华医学遗传学杂志,1996,13(3):161-163. 被引量:6
  • 2黄克武.吸烟致肺癌的基因基础[J].国外医学(呼吸系统分册),1996,16(4):169-171. 被引量:8
  • 3叶任高.内科学[M](第5版)[M].北京:人民卫生出版社,2000.313.
  • 4Kishimoto J,Murakami Y,Shiraishi M,et al. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinoma of the lung[J].Cancer Res,1992,52(9):4799~4804.
  • 5Peifer GP.p53 mutational spectra and the role of methylated CpG sequences[J].Mutat Res,2000,450(1):155~166.
  • 6Mitsudomi T,Oyama T,Kusano T,et al.Mutation of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer[J].J Natl Cancer Inst,1993,85(4):2018~2023.
  • 7Rollins LA,Leona-Kabler S,O'Sullivan MG,et al.Role of tumor suppressor genes in transplacental lung carcinogensis[J].Mol-Carcinog,1998,21(3):177~184.
  • 8Sekine I,Shao G,Fahey M,et al.What causes p53 mutations in patients with lung cancer[J].Oncal Rep,1998,5(5):1125~1128.
  • 9Murakami I,Hiyama K,Ishioka S,et al.p53 gene mutations are associated with shortened survival in patients with advanced non small cell lung cancer:analysis of medically managed patients[J].Clin Cancer Res,2000,6(2):526~530.
  • 10Kersting M,Friedl C,Kraus A,et al.Differential frequencies of p16(INK4a) promoter hypermethylation,p53 mutation,and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers[J].J Clin Oncol,2000,18(18):3221~3229.

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部